OXB to present at JMP Securities

RNS Number : 9633Q

Oxford Biomedica PLC

23 June 2015

 

 

Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London

Oxford, UK - 23 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP Securities Life Sciences Conference in New York at 1600-1630 ET (2100-2130 BST).

Tim Watts, Chief Financial Officer of Oxford BioMedica will also be in attendance at the 2nd Annual ROTH Healthcare Day, held in London on the 24th June 2015.

A live-streaming webcast of the JMP conferencepresentation will be available at http://wsw.com/webcast/jmp27/oxb.l. An archived copy of the presentation will also be made available on the Oxford BioMedica website following the event.

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that

are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.

 

END

 

 

NRAPKNDQKBKDCAB